Dry Eye Syndrome Market Set for Rapid Growth as Aging Population Demand Soars - Global Long-term Forecast to 2028 and 2032 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Dry Eye Syndrome Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

This research publication sheds light on the robust growth and pivotal trends propelling the sector forward, ensuring stakeholders are well-informed for decision-making.

Diverse Product Portfolio Boosts Dry Eye Syndrome Market Dynamics

Leveraging in-depth market data, the report delves into the extensive range of products designed to alleviate symptoms of Dry Eye Syndrome (DES), including innovative liquid drops, gel formulations, and advanced ointment solutions. These developments reflect the market's response to growing global demand, providing relief and effective therapy for those affected by the condition.

Surging Market Growth Driven by Key Demographic and Technological Factors

The study underscores the market's anticipated growth trajectory, citing a robust compound annual growth rate and identifying key drivers such as demographic shifts, digital screen usage proliferation, lifestyle modifications, and heightened medical awareness. It particularly spotlights the aging population's significant impact on the market's expansion, emphasizing the connection between age-associated DES prevalence and impending market opportunities.

Rapid Market Expansion in Asia-Pacific Region

Region-wise, the report indicates North America's dominance in the DES market during the previous year, while predicting Asia-Pacific to be a frontrunner in terms of growth rate over the forecast period. This points to an increasing awareness and developing healthcare infrastructure in these nations contributing to the market's expansion.

Comprehensive Coverage of Market Dynamics

The publication provides an extensive analysis of service providers in the DES market, including the diagnosis, treatment modalities, and prescription patterns focusing on improving patient quality of life. Moreover, the report lends insight into the geographical nuances that manifest in the demand and service provision within the global Dry Eye Syndrome sector.

Strategic Industry Developments

• The introduction of pathbreaking products like Cyclotears emphasizes the industry's push towards novel and efficient treatment options.
• Major market players are responding to consumer needs with preservative-free product launches, exemplified by the release of Systane's premium eye drops.
• Mergers and acquisitions, such as Novartis AG's strategic acquisition of Kedalion Therapeutics, signal a consolidation trend aimed at strengthening market positions while addressing the growing patient pool.

A selection of companies mentioned in this report includes

• Allergan plc
• Novartis AG
• Otsuka Pharmaceutical Co. Ltd.
• Santendo Pharmaceutical Co. Ltd.
• Sentiss Pharma Pvt. Ltd.
• Johnson & Johnson
• Alcon Vision LLC
• Akorn Operating Company LLC
• Sun Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• AbbVie Inc.
• GlaxoSmithKline plc
• I-MED Pharma Inc.
• Hoffmann-La Roche AG
• Acadia Pharmaceuticals Inc.
• AFT Pharmaceuticals
• Horus Pharma
• Mitotech
• Novaliq GmbH
• OASIS Medical
• Prestige Consumer Healthcare
• VISUfarma
• Alimera Science
• Auven Therapeutics
• Kala Pharmaceuticals Inc.
• Nicox S.A.
• Emisphere Technologies Inc.
• EyeGate Pharmaceuticals Inc.
• ReVision Therapeutics Inc.
• Avedro Inc.
• Itear Medical
• Transcend Medical Inc.

For more information about this report visit https://www.researchandmarkets.com/r/s16lww

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.